CLRB - Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Cellectar Biosciences shares slide ([[CLRB]] -13.2%) after posting data from its mid-stage study of CLR 131 in patients with Waldenstrom’s macroglobulinemia ((WM)), a rare and incurable disease, at the American Society of Clinical Oncology ((ASCO)) Annual meeting.The pivotal trial, which will enroll 50 WM patients, is designed as a global, non-comparator, single arm, expansion cohort of the currently ongoing Phase 2 CLOVER-1 study of CLR 131.Data showed 100% (6/6) overall response rate, 83.3% (5/6) major response rate and a 16.7% (1/6) complete response rate.Median time to initial response was 22 days after first infusion, while median time to major response, as defined as at least a 50% reduction in IgM, was 44 days after first infusion.Progression free survival ((PFS)) for both MYD88 wild type patients as well as the high-risk subgroup has not been reached after 18 months; PFS for multidrug refractory patients was 11 months.The company also highlighted that Mean treatment free remission is 1.1 years

For further details see:

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress